Response to higher dose of entecavir 1.0 mg daily in patients with partial response to entecavir 0.5 mg daily

Journal of Clinical Gastroenterology

Volumn 47, Issue 5, 2013, Pages 461-465

  Ha, Nghiem B ^a,b   Ha, Nghi B ^b,d   Trinh, Huy N ^b,c   Nguyen, Huy A ^c   Nguyen, Khanh K ^c   Nguyen, Mindie H ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b Pacific Health Foundation   (United States)

^c San Jose Gastroenterology   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

hepatitis B virus; increase dosage; partial response; rescue therapy

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN; TENOFOVIR; VIRUS DNA;

ADULT; AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LACTIC ACIDOSIS; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROCONVERSION; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA; YOUNG ADULT;

EID: 84876407494     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318266fd31     Document Type: Article

References (29)

1. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337: 1733-1745
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97-107
3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-2576
4. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med. 2004;350: 1118-1129
5. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507-539
6. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73
7. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678-686
8. Yuan HJ, Yuen MF, Ka-Ho Wong D, et al. The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. J Viral Hepat. 2005; 12:373-379
9. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6:1315-1341
10. Lok AS, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology. 2009;50:661-662
11. Mommeja-Marin H, Mondou E, Blum MR, et al. DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature. Hepatology. 2003;37:1309-1319
12. Nguyen MH, Keeffe EB. Chronic hepatitis B: Early viral suppression and long-Term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat. 2009;16:149-155
13. Heathcote EJ. Treatment of hepatitis B: The next five years. Clin Med. 2007;7:472-477
14. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001-1010
15. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011-1020
16. Leung N, Peng CY, Hann HW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology. 2009;49:72-79
17. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133:1437-1444
18. Yokosuka O, Takaguchi K, Fujioka S, et al. Long-Term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J Hepatol. 2010;52:791-799
19. Yao G, Chen C, Lu W, et al. Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naive Chinese patients with chronic hepatitis B: A randomized, multicenter study. Hepatol Int. 2008;2:486-493
20. Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010;52:176-182
21. Tenney DJ, Rose RE, Baldick CJ, et al. Long-Term monitoring shows hepatitis B virus resistance to entecavir in nucleosidenaive patients is rare through 5 years of therapy. Hepatology. 2009;49:1503-1514
22. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology. 2006;44:1656-1665
23. de Man RA, Wolters LM, Nevens F, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology. 2001;34: 578-582
24. Yan JH, Bifano M, Olsen S, et al. Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. J Clin Pharmacol. 2006;46:1250-1258
25. Sheen E, Trinh HN, Nguyen TT, et al. The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adevofir. Aliment Pharmacol Ther. 2011;34:767-774
26. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother. 2004;48:3498-3507
27. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422-430
28. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130:2039-2049
29. Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology. 2011;54:443-451